Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 603-373-3 | CAS number: 129909-90-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Specific investigations: other studies
Administrative data
Link to relevant study record(s)
Description of key information
Section 7.9.3 - Specific investiations: other:
KS - mech.rat. Croutch & Christenson, 1999. KL.1;
SS - mech. in vitro. Freyberger, 1998. KS.2
Additional information
The mechanistic study (Croutch & Christenson, 1999) further characterises amicarbazone’s effects on the thyroid. In this study no treatment related effects were observed on the thyroid gland weight or microscopic changes observed in this organ at any treatment level. Thyroid to blood ratios of125I in treated groups were comparable throughout all treatment groups to the respective concurrent control groups, indicating the increase in thyroid hormones were most likely not due to increased synthesis, but rather differences in thyroid hormones being metabolised at another site. The liver is implicated as the extra-thyroidal site based on increased liver weights and UDP-glucuronosyltransferase activity.
The results of the in vitro mechanistic study (Freyberger, 1998) support the conclusion that MKH 3586 does not affect the major enzymes involved in the synthesis or regulation of thyroid hormones, and strengthens the findings of thein vivosub-chronic mechanistic study which indicated that amicarbazone is conjugated by UDP- glucuronosyl transferase. This enzyme is also responsible for the conjugation of T3 / T4, therefore it would appear that amicarbazone competes for this enzyme with these thyroidal hormones. As a result less UDP- glucuronosyl transferase is available to conjugate T3 / T4, with serum levels increasing. This leads to hypertrophy of the liver, through the up regulation of UDP- glucuronosyl transferase.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
